Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREPARE-Germany: Durability of Immunity and Booster Dose of Ervebo in Occupational Ebola Risk
2024-517352-35-00Phase 3Completed
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Oct 2024
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Ebola Zaire vaccine (live, attenuated) in Ebola virus disease (EVD) (2 arms), sponsored by University Medical Center Hamburg-Eppendorf. Primary endpoints: Binding anti-EBOV antibody titers over 24 months and Anti-EBOV neutralizing antibody titers over 24 months. Started Oct 2024; status: completed.
02
Drugs
Ebola Zaire vaccine (live, attenuated)
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on 2024-517352-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517352-35-00.